Leukotriene synthesis inhibitor decreases vasopressin release in the early phase of sepsis.

J Neuroimmunol

Departamento de Morfologia, Estomatologia e Fisiologia, Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, Avenida do Café s/n, CEP 14040-900, Ribeirão Preto, SP, Brazil.

Published: September 2011

The aim was to analyze the effect of leukotriene synthesis inhibitor administered intraperitoneally in vasopressin release during sepsis. Male Wistar rats received injections of MK-886 (1.0, 2.0 or 4.0 mg/kg) or vehicle (DMSO 5%) 1 h before cecal ligation and puncture. There was some variation on the survival rate depending on the dose used but the drug did not modify the hematocrit, osmolality, serum sodium and nitrate, plasma protein, and neutrophil recruitment, in any dose. Nevertheless, vasopressin (AVP) release decreased in a dose-response manner in the early phase of sepsis. These results support the suggestion that leukotrienes (LTs) are involved in AVP release during sepsis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2011.08.001DOI Listing

Publication Analysis

Top Keywords

leukotriene synthesis
8
synthesis inhibitor
8
vasopressin release
8
early phase
8
phase sepsis
8
release sepsis
8
avp release
8
inhibitor decreases
4
decreases vasopressin
4
release
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!